Comparative Pharmacology
Head-to-head clinical analysis: K TAB versus KLOR CON M15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K TAB versus KLOR CON M15.
K-TAB vs KLOR-CON M15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
Potassium is the major intracellular cation; it is necessary for conduction of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, maintenance of normal renal function, acid-base balance, and carbohydrate metabolism.
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
Oral: 15 mEq (1 tablet) once daily or as directed; range 15-100 mEq/day divided doses. Maximum 150 mEq/day.
None Documented
None Documented
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
Not applicable; potassium is not eliminated by first-order kinetics. Serum potassium decline depends on redistribution and renal function, with a half-life of approximately 1-1.5 hours for acute redistribution but prolonged in renal impairment.
Renal (90% unchanged), fecal (10% as metabolites)
Renal: >90% as potassium ions; fecal: <5%; biliary: negligible.
Category C
Category C
Potassium Supplement
Potassium Supplement